S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:CGC

Canopy Growth Competitors

$33.39
-1.23 (-3.55 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.81
Now: $33.39
$35.08
50-Day Range
$24.26
MA: $26.71
$34.62
52-Week Range
$9.00
Now: $33.39
$35.08
Volume7.44 million shs
Average Volume9.13 million shs
Market Capitalization$12.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.44

Competitors

Canopy Growth (NASDAQ:CGC) Vs. CRON, TLRY, ACB, USNA, HEXO, and SNDL

Should you be buying CGC stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Canopy Growth, including Cronos Group (CRON), Tilray (TLRY), Aurora Cannabis (ACB), USANA Health Sciences (USNA), HEXO (HEXO), and Sundial Growers (SNDL).

Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Canopy Growth has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Cronos Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million41.80$-993,370,000.00$1.3225.30
Cronos Group$25.64 million151.66$1.17 billion$0.6716.31

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Cronos Group266.31%-1.61%-1.41%

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 11.8% of Cronos Group shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Comparatively, 7.9% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Canopy Growth and Cronos Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth39312.13
Cronos Group24202.00

Canopy Growth presently has a consensus price target of $31.51, indicating a potential downside of 5.63%. Cronos Group has a consensus price target of $8.1875, indicating a potential downside of 25.09%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Summary

Cronos Group beats Canopy Growth on 8 of the 15 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Canopy Growth has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Tilray's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million41.80$-993,370,000.00$1.3225.30
Tilray$166.98 million15.75$-321,170,000.00($1.69)-11.66

Tilray has lower revenue, but higher earnings than Canopy Growth. Tilray is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Tilray-259.60%-77.77%-21.45%

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 10.4% of Tilray shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Comparatively, 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Canopy Growth and Tilray, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth39312.13
Tilray210101.92

Canopy Growth presently has a consensus price target of $31.51, indicating a potential downside of 5.63%. Tilray has a consensus price target of $12.2720, indicating a potential downside of 37.71%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts clearly believe Canopy Growth is more favorable than Tilray.

Summary

Canopy Growth beats Tilray on 9 of the 15 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Canopy Growth has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Aurora Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million41.80$-993,370,000.00$1.3225.30
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21

Canopy Growth has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Canopy Growth and Aurora Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth39312.13
Aurora Cannabis412101.82

Canopy Growth presently has a consensus price target of $31.51, indicating a potential downside of 5.63%. Aurora Cannabis has a consensus price target of $12.6564, indicating a potential upside of 5.12%. Given Aurora Cannabis' higher probable upside, analysts clearly believe Aurora Cannabis is more favorable than Canopy Growth.

Summary

Canopy Growth beats Aurora Cannabis on 11 of the 15 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Canopy Growth has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and USANA Health Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million41.80$-993,370,000.00$1.3225.30
USANA Health Sciences$1.06 billion1.57$100.53 million$4.4117.99

USANA Health Sciences has higher revenue and earnings than Canopy Growth. USANA Health Sciences is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
USANA Health Sciences10.35%32.87%22.28%

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 55.5% of USANA Health Sciences shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Comparatively, 45.4% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Canopy Growth and USANA Health Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth39312.13
USANA Health Sciences00203.00

Canopy Growth presently has a consensus price target of $31.51, indicating a potential downside of 5.63%. USANA Health Sciences has a consensus price target of $107.00, indicating a potential upside of 34.88%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, analysts clearly believe USANA Health Sciences is more favorable than Canopy Growth.

Summary

USANA Health Sciences beats Canopy Growth on 11 of the 15 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and HEXO (NYSE:HEXO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Canopy Growth has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and HEXO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million41.80$-993,370,000.00$1.3225.30
HEXO$60.46 million14.57$-406,370,000.00($0.96)-7.51

HEXO has lower revenue, but higher earnings than Canopy Growth. HEXO is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
HEXO-517.61%-13.15%-10.35%

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 35.3% of HEXO shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Canopy Growth and HEXO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth39312.13
HEXO69101.69

Canopy Growth presently has a consensus price target of $31.51, indicating a potential downside of 5.63%. HEXO has a consensus price target of $1.15, indicating a potential downside of 84.05%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts clearly believe Canopy Growth is more favorable than HEXO.

Summary

Canopy Growth beats HEXO on 12 of the 15 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Canopy Growth has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Sundial Growers' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million41.80$-993,370,000.00$1.3225.30
Sundial Growers$75.86 million6.65$-204,570,000.00N/AN/A

Sundial Growers has lower revenue, but higher earnings than Canopy Growth.

Profitability

This table compares Canopy Growth and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Sundial Growers-362.49%-179.71%-79.40%

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 10.7% of Sundial Growers shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Canopy Growth and Sundial Growers, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth39312.13
Sundial Growers13001.75

Canopy Growth presently has a consensus price target of $31.51, indicating a potential downside of 5.63%. Sundial Growers has a consensus price target of $1.25, indicating a potential upside of 75.17%. Given Sundial Growers' higher probable upside, analysts clearly believe Sundial Growers is more favorable than Canopy Growth.

Summary

Canopy Growth beats Sundial Growers on 10 of the 14 factors compared between the two stocks.


Canopy Growth Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cronos Group logo
CRON
Cronos Group
0.7$10.93-3.0%$3.89 billion$25.64 million45.54Decrease in Short Interest
Tilray logo
TLRY
Tilray
0.8$19.70-5.8%$2.63 billion$166.98 million-4.04Analyst Downgrade
Heavy News Reporting
Aurora Cannabis logo
ACB
Aurora Cannabis
1.1$12.04-0.7%$1.71 billion$207.89 million-0.49Analyst Revision
Heavy News Reporting
USANA Health Sciences logo
USNA
USANA Health Sciences
1.8$79.33-0.2%$1.67 billion$1.06 billion14.69
HEXO
HEXO
0.7$7.21-1.1%$880.80 million$60.46 million-1.48Increase in Short Interest
Heavy News Reporting
SNDL
Sundial Growers
1.3$0.71-2.8%$504.35 million$75.86 million-0.24
ChromaDex logo
CDXC
ChromaDex
1.3$4.67-0.2%$288.55 million$46.29 million-12.29
MediWound logo
MDWD
MediWound
1.1$5.05-0.4%$137.42 million$31.79 million-12.62Analyst Revision
NAII
Natural Alternatives International
0.4$12.70-0.8%$82.25 million$118.88 million158.77Decrease in Short Interest
HAPP
Happiness Biotech Group
0.6$2.02-3.5%$52.32 million$65.06 million0.00
MTEX
Mannatech
1.1$18.07-0.6%$37.73 million$157.73 million5.56Decrease in Short Interest
CYAN
Cyanotech
0.9$3.19-1.3%$19.45 million$31.90 million31.90Decrease in Short Interest
Heavy News Reporting
This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.